John C. Byrd

6.2k total citations · 1 hit paper
81 papers, 3.7k citations indexed

About

John C. Byrd is a scholar working on Genetics, Hematology and Molecular Biology. According to data from OpenAlex, John C. Byrd has authored 81 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Genetics, 32 papers in Hematology and 24 papers in Molecular Biology. Recurrent topics in John C. Byrd's work include Chronic Lymphocytic Leukemia Research (47 papers), Acute Myeloid Leukemia Research (21 papers) and Lymphoma Diagnosis and Treatment (19 papers). John C. Byrd is often cited by papers focused on Chronic Lymphocytic Leukemia Research (47 papers), Acute Myeloid Leukemia Research (21 papers) and Lymphoma Diagnosis and Treatment (19 papers). John C. Byrd collaborates with scholars based in United States, United Kingdom and Italy. John C. Byrd's co-authors include Kristie A. Blum, Gerard Lozanski, Guido Marcucci, Michael R. Grever, David Lucas, John C. Reed, Andrew P. Mone, Melanie E. Davis, Shinichi Kitada and Mark R. Parthun and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

John C. Byrd

75 papers receiving 3.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

2002 1.2k citations John C. Byrd Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John C. Byrd United States	19	1.7k	1.5k	1.4k	1.0k	720	81	3.7k
Sergej Konoplev United States	35	2.2k 1.3×	1.4k 0.9×	1.2k 0.9×	964 0.9×	1.4k 1.9×	154	4.6k
Stefan Faderl United States	26	2.0k 1.2×	1.2k 0.8×	1.7k 1.3×	1.0k 1.0×	548 0.8×	115	3.6k
H. Kantarjian United States	29	2.4k 1.5×	995 0.7×	2.1k 1.6×	676 0.7×	637 0.9×	120	3.9k
Enrico Tiacci Italy	27	811 0.5×	1.1k 0.8×	1.1k 0.8×	1.1k 1.0×	703 1.0×	77	2.8k
Preetesh Jain United States	32	1.4k 0.9×	668 0.5×	2.2k 1.6×	1.5k 1.5×	1.0k 1.4×	181	3.7k
Nikolas von Bubnoff Germany	31	2.0k 1.2×	1.1k 0.8×	1.3k 1.0×	481 0.5×	1.1k 1.5×	138	4.1k
Jalaja Potluri United States	27	2.7k 1.6×	1.6k 1.1×	1.4k 1.1×	606 0.6×	654 0.9×	79	3.7k
Miloslav Beran United States	38	3.3k 2.0×	2.0k 1.4×	2.6k 1.9×	1.1k 1.1×	1.1k 1.5×	106	5.6k
Laurent Knoops Belgium	26	1.4k 0.9×	1.6k 1.1×	1.9k 1.4×	423 0.4×	638 0.9×	53	3.4k
Leslie A. Andritsos United States	30	866 0.5×	967 0.7×	2.1k 1.5×	1.5k 1.4×	1.0k 1.4×	161	3.5k

Countries citing papers authored by John C. Byrd

Since Specialization

Citations

This map shows the geographic impact of John C. Byrd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John C. Byrd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John C. Byrd more than expected).

Fields of papers citing papers by John C. Byrd

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John C. Byrd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John C. Byrd. The network helps show where John C. Byrd may publish in the future.

Co-authorship network of co-authors of John C. Byrd

This figure shows the co-authorship network connecting the top 25 collaborators of John C. Byrd. A scholar is included among the top collaborators of John C. Byrd based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John C. Byrd. John C. Byrd is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Nicolet, Deedra, Daelynn R. Buelow, Shelley Orwick, et al.. (2025). Prognostic, biological, and structural implications of FLT3-JMD point mutations in acute myeloid leukemia: an analysis of Alliance studies. Leukemia. 39(3). 623–631. 1 indexed citations

Agarwal, Puneet, Kathleen Hueneman, Niels Asger Jakobsen, et al.. (2025). Microbial metabolite drives ageing-related clonal haematopoiesis via ALPK1. Nature. 642(8066). 201–211. 11 indexed citations

Ruz, Patrick, Adam S. Kittai, Kerry A. Rogers, et al.. (2024). Atrial fibrillation burden and clinical outcomes following BTK inhibitor initiation. Leukemia. 38(10). 2141–2149. 5 indexed citations

Mansour, Anthony G., Ying Huang, Adam S. Kittai, et al.. (2024). Outcomes of Patients with Chronic Lymphocytic Leukemia Discontinuing Bruton Tyrosine Kinase Inhibitors Due to Adverse Effects. Blood. 144(Supplement 1). 4629–4629.

Woyach, Jennifer A., Paolo Ghia, John C. Byrd, et al.. (2023). B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy. Clinical Cancer Research. 29(16). 3065–3073. 7 indexed citations

Woyach, Jennifer A., Deborah M. Stephens, Ian W. Flinn, et al.. (2023). First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non–Hodgkin Lymphoma. Cancer Discovery. 14(1). 66–75. 29 indexed citations

Kittai, Adam S., Seema A. Bhat, Michael R. Grever, et al.. (2023). Characteristics and outcomes of patients with CLL and CDKN2A/B deletion by fluorescence in situ hybridization. Blood Advances. 7(23). 7239–7242. 4 indexed citations

Seymour, John F., John C. Byrd, Paolo Ghia, et al.. (2023). Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial. Blood. 142(8). 687–699. 62 indexed citations

Vibhute, Sandip, Tiffany Hughes, Susheela Tridandapani, et al.. (2023). The Potent Dihydroorotate Dehydrogenase Inhibitor, Hosu-53, Exhibits Compelling Monotherapy Efficacy in Multiple Myeloma and Augments CD47 Targeted Therapy. Blood. 142(Supplement 1). 4692–4692.

10.

Özer, Hatice Gülçin, Arletta Lozanski, Shelley Orwick, et al.. (2022). Clonal hematopoiesis of indeterminate potential in the companion dog. Leukemia. 36(5). 1401–1403. 3 indexed citations

11.

Özer, Hatice Gülçin, Pierluigi Gasparini, Giovanni Nigita, et al.. (2022). HDAC1 regulates the chromatin landscape to control transcriptional dependencies in chronic lymphocytic leukemia. Blood Advances. 7(12). 2897–2911. 7 indexed citations

12.

Curran, Emily, et al.. (2022). 649TiP A phase I/Ib study evaluating the safety, pharmacokinetics, and preliminary efficacy of LP-118 in subjects with relapsed or refractory haematological malignancies. Annals of Oncology. 33. S837–S838. 1 indexed citations

13.

Patel, Krish, Jean‐Marie Michot, Asher Chanan‐Khan, et al.. (2021). Safety and Anti-Tumor Activity of Plamotamab (XmAb13676), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Subjects with Relapsed/Refractory Non-Hodgkin's Lymphoma. Blood. 138(Supplement 1). 2494–2494. 19 indexed citations

14.

Miller, Cecelia, Ying Huang, Amy S. Ruppert, et al.. (2021). Significance of chromosome 2p gain in ibrutinib-treated chronic lymphocytic leukemia patients. Leukemia. 35(11). 3287–3290.

15.

Walker, Alison R., Rebecca B. Klisovic, Jeffrey S. Johnston, et al.. (2012). Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia. Leukemia & lymphoma. 54(9). 1996–2002. 24 indexed citations

16.

Wang, Liwen, Sean W. Harshman, Shujun Liu, et al.. (2010). Assaying pharmacodynamic endpoints with targeted therapy: Flavopiridol and 17AAG induced dephosphorylation of histone H1.5 in acute myeloid leukemia. PROTEOMICS. 10(23). 4281–4292. 13 indexed citations

17.

Johnson, Amy J., Amy J. Wagner, Carolyn Cheney, et al.. (2007). Rituximab and 17‐allylamino‐17‐demethoxygeldanamycin induce synergistic apoptosis in B‐cell chronic lymphocytic leukaemia. British Journal of Haematology. 139(5). 837–844. 18 indexed citations

18.

Neviani, Paolo, Ramasamy Santhanam, Joshua J. Oaks, et al.. (2007). FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome–positive acute lymphocytic leukemia. Journal of Clinical Investigation. 117(9). 2408–2421. 269 indexed citations

19.

Lucas, David, Melanie E. Davis, Mark R. Parthun, et al.. (2004). The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells. Leukemia. 18(7). 1207–1214. 115 indexed citations

20.

Byrd, John C., William J. Edenfield, Nancy Dow, Cheryl Aylesworth, & Nancy A. Dawson. (1996). Extramedullary Myeloid Cell Tumors in Myelodysplastic-Syndromes: Not a True Indication of Impending Acute Myeloid Leukemia. Leukemia & lymphoma. 21(1-2). 153–159. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact